Indoxyl Sulfate Inhibits Nitric Oxide Production and Cell Viability by Inducing Oxidative Stress in Vascular Endothelial Cells

American Journal of Nephrology - Tập 29 Số 6 - Trang 551-557 - 2009
Zohra Tumur1, Toshimitsu Niwa
1Department of Clinical Preventive Medicine, Nagoya University Hospital, Nagoya, Japan.

Tóm tắt

<i>Background/Aim:</i> Cardiovascular disease is a major cause of mortality in chronic kidney disease patients. Oxidative stress and nitric oxide (NO) deficiency play an important role in vascular endothelial cell dysfunction in chronic kidney disease. To determine if the uremic toxin indoxyl sulfate (IS) induces oxidative stress and inhibits NO production and cell viability in human umbilical vein endothelial cells (HUVEC). <i>Methods:</i> The production of reactive oxygen species (ROS), superoxide, NO and peroxynitrite was measured using a fluorescence microplate reader. The expression of NADPH oxidases (Nox4, Nox2) was analyzed by quantitative reverse transcription-polymerase chain reaction. Cell viability was examined by 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate assay. <i>Results:</i> IS induced ROS generation in HUVEC. An inhibitor of NADPH oxidase showed an inhibitory effect on IS-induced ROS production. However, the inhibitors of xanthine oxidase, mitochondrial electron transport and NO synthase did not show any significant effect on IS-induced ROS production. Antioxidants such as vitamin E, N-acetyl-<i>L</i>-cysteine and vitamin C inhibited IS-induced ROS production. IS induced the expression of Nox4 mRNA and the production of superoxide and peroxynitrite in HUVEC. IS inhibited NO production in HUVEC. IS inhibited cell viability, and antioxidants preserve the inhibitory effect of IS on cell viability. <i>Conclusions:</i> IS inhibits NO production and cell viability by inducing ROS through induction of Nox4 in HUVEC.

Từ khóa


Tài liệu tham khảo

10.1111%2Fj.1542-4758.2006.01173.x

10.1159%2F000063552

10.1038%2Fsj.cdd.4400581

10.1152%2Fajprenal.00424.2007

10.1016%2Fj.semnephrol.2004.04.007

10.1161%2F01.ATV.0000141843.77133.fc

10.1152%2Fajpheart.00548.2005

10.1097%2F01.ASN.0000022017.96399.B2

10.1159%2F000112823

10.1152%2Fajprenal.00281.2004

10.1046%2Fj.1523-1755.2003.00906.x

10.1111%2Fj.1538-7836.2007.02540.x

10.1007%2Fs11095-007-9248-x

10.1159%2F000189284

10.1097%2F01.hco.0000179821.11071.79

10.1016%2FS1567-5688%2803%2900034-5

10.1111%2Fj.1523-1755.2004.00399.x

10.1016%2Fj.cardiores.2006.05.004

10.1016%2Fj.freeradbiomed.2007.06.001

10.1161%2F01.CIR.0000105680.92873.70

10.1161%2F01.RES.87.10.840

10.1089%2Fars.2007.1989

10.1007%2Fs00125-004-1525-1

10.1002%2Fjcp.10119

10.1038%2Fnrd2222